Therefore, these data indicate that IL7-Fc further enhanced rhIL-2-mediated anti-tumor responses by expanding transferred activated pmel-1 CD8+ T cells and endogenous CD8+ T cells along with their activation and differentiation, which might require the presentation of tumor-associated antigens in TDLN. The gene discussed is IL7; the disease is neoplasm.